SCHEMBL3500224

SCHEMBL3500224

Cc1cc(C(N)(CN)c2cc(C)[nH]n2)n[nH]1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 1/20 0.38
▸ HCAR2 Q8TDS4 2/20 0.34
▸ DAO P14920 1/20 0.34
▸ NPC1 O15118 2/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ RAB9A P51151 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ PRMT5 O14744 1/20 0.31
▸ WDR77 Q9BQA1 1/20 0.31
▸ HRH1 P35367 1/20 0.31
▸ HRH4 Q9H3N8 1/20 0.31
▸ MPI P34949 1/20 0.30
▸ DHODH Q02127 1/20 0.30
▸ PDE10A Q9Y233 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3500648 0.98 MAPT (0.37) MAPTHCAR2DAONPC1L3MBTL1
SCHEMBL3500946 0.81 HCAR2 (0.41) HCAR2HPGDTSHR
Hydrochloric Acid SCHEMBL3501057 0.76 HPGD (0.33) HPGDTSHR
Hydrochloric Acid SCHEMBL3500954 0.73 SMN1; SMN2 (0.53) MAPTNPC1KDM4EGAARAB9A
SCHEMBL179497 0.72 HPGD (0.50) MAPTHCAR2DAONPC1L3MBTL1
SCHEMBL192831 0.70 DHODH (0.44) MAPTHCAR2DAONPC1L3MBTL1
Hydrochloric Acid SCHEMBL3498403 0.70 HPGD (0.65) HCAR2DAOHPGDTSHR
Hydrochloric Acid SCHEMBL3502428 0.69 HCAR2 (0.40) HCAR2
SCHEMBL21233312 0.68 MAPT (0.45) MAPTHCAR2DAONPC1L3MBTL1
SCHEMBL13184146 0.68 MAPT (0.45) MAPTHCAR2DAONPC1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100144793-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS AC IMMUNE SA (CH) 2010-06-10 — — US disclosed
EP-2121619-A2 COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS AC Immune S.A. (CH) 2009-11-25 — — EP disclosed
WO-2008061796-A2 COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS AC IMMUNE SA (CH) 2008-05-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144793-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS APP, BACE1, APBA1 MAPT 19/4885HCAR2 700/4885DAO 1078/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback